TY - JOUR
T1 - The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.
AU - Aprahamian, Tamar R.
AU - Zhong, Xuemei
AU - Amir, Shahzada
AU - Binder, Christoph J.
AU - Chiang, Lo-Ku
AU - Al-Riyami, Lamyaa
AU - Gharakhanian, Raffi
AU - Harnett, Margaret M.
AU - Harnett, William
AU - Rifkin, Ian R.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.
AB - ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.
KW - atherosclerosis
KW - ES-62
KW - helminth
KW - systemic lupus erythematosus
UR - http://www.sciencedirect.com/science/article/pii/S002075191500020X
U2 - 10.1016/j.ijpara.2014.12.006
DO - 10.1016/j.ijpara.2014.12.006
M3 - Article
SN - 0020-7519
VL - 45
SP - 203
EP - 207
JO - International Journal for Parasitology
JF - International Journal for Parasitology
IS - 4
ER -